boehringer ingelheim is a company I would keep an eye on for PI too. From what I have heard they were one of the early success stories (I believe they had 1 month tox issues in monkeys after promising Phase 1 results). ITMN has done 3 month+ tox with no issues reported.
I believe Pharmasset only has Polymerase compounds in development. It is interesting that their earlier stage followon is not partnered with Roche. I guess that is why people expect Roche to just buy them out at some point. It would be an odd situation if their lead Polymerase is partnered with Roche and a followon with a competitor. I don't know if Roche has rights to it.
>Will follow-on pi's (after vrtx/sgp) get to market vs placebo or do you think they need to go up against telaprevir?<
It looks like ITMN-191 will be able to go against the current SoC in phase-3 if Roche doesn’t drop the ball. The PI’s after that (including those from IDIX) will probably have to go for non-inferiority vs a newer regimen.
>Biolex just raised a bunch of committed money, so they ought to at least be able to get to market.<
I have Locteron ranked #3 (only one notch behind ITMN-191), so we’re in agreement there :- )
Market Data 
Markets 
AI
